Research themes

Research interests

Research groups

Research summary

My research interests and activities primarily focus on translational aspects of antimicrobial therapy of septic shock. In the past, I have also focused on a bench and bedside level at questions related to myocardial dysfunction in sepsis and septic shock. These latter studies continue with the co-operation of basic science investigators. More recent efforts have been focused basic and clinical aspects of pandemic (2009) H1N1 influenza and SARS-CoV-2 (COVID19) infection.

As noted, my primary interest is optimization of antimicrobial therapy in the context of septic shock. This question is being addressed in small animal and clinical studies. This question is being addressed in small animal and clinical studies. The basic premise of this work is that current antimicrobial therapy of septic shock is suboptimal in that it fails to recognize that a key determinant of outcome is rapidity of microbial clearance following onset of shock. In this theoretical model, the microbial biomass can be considered to be the central driving force in the development of septic shock. Based on an adaptation of Wigger’s classic hemorrhagic model of irreversible shock, there is only a limited period of time during which septic shock can be reversed without irreparable injury. This model of the disease process naturally leads to many testable hypotheses that span questions of molecular biology to clinical epidemiology. In order to investigate these hypotheses, an integrated program of research from molecular biology through human and rodent cardiovascular pathophysiology to clinical epidemiology is being developed. The primary tools for this effort are a small animal model of septic shock (both mouse and rat) and a newly developed clinical septic shock database drawn from multiple world-wide contributing sites which we have developed. This clinical database, currently encompassing >9000 individual patients, is by far the largest and most complete in existence. Our theoretical model of septic shock implies that more rapid initiation of antimicrobial therapy after onset of hypotension should result in improved outcome. We have utilized our mouse and rat models of septic shock to confirm this hypothesis. Further, we have been able to retrospectively confirm these findings in our septic shock human dataset. We have further been able to demonstrate in our animal model (and obtain supportive evidence from our clinical database) that more effective antimicrobial killing in septic shock also yields improved outcome. My seminal paper on the adverse impact of delays in initiation of appropriate antimicrobial therapy in human septic shock (Kumar et al, Critical Care Medicine 2006) with over 5000 citations is recognized as among the top 10 most highly cited papers in both the field of sepsis and antibiotic research.


Dr. Anand Kumar is a professor of medicine (critical care medicine and infectious diseases), in the departments of medical microbiology and infectious diseases, and pharmacology and therapeutics. He is an attending physician at the Health Sciences Centre and St-Boniface Hospital, Winnipeg, Manitoba, Canada. He earned his medical degree from the University of Toronto in Ontario, Canada and completed his residency in internal medicine at the Toronto Hospital—University of Toronto.

Dr. Kumar subsequently completed fellowships in critical care medicine and cardiovascular research at Rush-Presbyterian-St Luke’s Medical Center in Chicago and infectious diseases at the University of Wisconsin Hospital and Clinics in Madison, Wisconsin. Dr. Kumar is trained in internal medicine, critical care medicine and infectious diseases with translational research interests in sepsis/septic shock, life-threatening infections and severe epidemic/pandemic infections. He has published over 450 original research manuscripts, reviews/chapters and abstracts



  • Young Investigator Educational Scholarship Award, Society of Critical Care Medicine (1993)
  • DuPont Pharmaceuticals/ACCP Young Investigator Award, American College of Chest Physicians (1993)
  • DuPont Pharmaceuticals/ACCP Critical Care Research Award Finalist, American College of Chest Physicians (1993)
  • Cecile Lehman Mayer Award Finalist, American College of Chest Physicians (1993)
  • Internal Medicine Specialty Award, Society of Critical Care Medicine (1994)
  • Canadian Critical Care Society Arrow Young Investigator Award (1994)
  • In-Training Young Investigator Award, Society of Critical Care Medicine (1995)
  • Young Investigator Award, Society of Critical Care Medicine 1998
  • Best Abstract, 2nd place, Toronto Critical Care Medicine Symposium, as senior author (1st author John Ronald) (2004)
  • Soffer Award for best abstract nominee, ACCP Annual Symposium, as senior author (1st author Sat Sharma) (2004)
  • Internal Medicine Award, Society of Critical Care Medicine (2005)

Contact us

Internal Medicine
Room GC430, Health Sciences Centre
820 Sherbrook Street
University of Manitoba
Winnipeg, MB R3A 1R9 Canada